Provocative (Drug) testing in inherited arrhythmias

Wataru Shimizu, Michael J. Ackerman

Research output: Chapter in Book/Report/Conference proceedingChapter


Molecular genetic studies have established a link between a number of heritable channelopathies, including congenital long QT syndrome (LQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular tachycardia (CPVT), and mutations in genes encoding for ion channels or other membrane components, therefore, have become a golden standard for diagnosing these channelopathies. Clinical diagnosis by standard 12-lead electrocardiography (ECG) at baseline misses some patients, who are genetically affected by these channelopathies (so called concealed form). Therefore, there is a strong need to devise clinical tools to improve the sensitivity of clinical tests to establish the diagnosis of these heritable channelopathies. Provocative testing with catecholamines and pharmacologic testing with sodium channel blockers are critical diagnostic tests in the evaluation of these heritable channelopathies and enable to unmask LQTS, BrS, and CPVT in their concealed state.

Original languageEnglish (US)
Title of host publicationElectrical Diseases of the Heart
Subtitle of host publicationVolume 2: Diagnosis and Treatment, Second Edition
PublisherSpringer-Verlag London Ltd
Number of pages12
ISBN (Electronic)9781447149781
ISBN (Print)9781447149774
StatePublished - Jan 1 2013


  • Arrhythmia
  • Brugada syndrome
  • Catecholamines
  • Diagnosis
  • Genes
  • Long-QT syndrome
  • QT interval
  • ST segment
  • Sodium channel blocker
  • Torsade de pointes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Provocative (Drug) testing in inherited arrhythmias'. Together they form a unique fingerprint.

Cite this